Perjeta Dosing and Administration Recommendations

This article responds to your request for information on Perjeta® (pertuzumab) intravenous infusion and dosing and administration recommendations.


Please refer to the locally approved dosing information provided in the Perjeta package insert or prescribing information. Any deviation from this information is considered off-label and any treatment decisions based on such deviations are the full responsibility of the prescribing physician.

Download article Download

Last updated August 15, 2023


  • There are no recommendations for administering premedications in the Perjeta prescribing information.
    • The recommended loading dose of Perjeta is 840 mg, followed every 3 weeks thereafter by a maintenance dose of 420 mg.
      • If a patient experiences a delayed or missed dose, they may need to be administered the loading doses of Perjeta and Herceptin again.
        • Observe patients during Perjeta administration and for 60 minutes following the administration of a loading dose, or 30 minutes following a maintenance dose.

          Administering premedication

          There are no recommendations for administering premedications in the Perjeta prescribing information.[1]

          Premedication protocol in the pivotal studies

          Pivotal clinical studies, including CLEOPATRA and APHINITY, did not require that patients were premedicated prior to receiving Perjeta.[2,3]  While the studies did not require premedications, they were permitted to be used in line with local clinical practice. This included, but was not limited to

          • paracetamol and other analgesics
            • diphenhydramine, chlorpheniramine or other anti-histamines, and
              • anti-emetics.

                Loading and maintenance dose

                The recommended loading dose of Perjeta is 840 mg administered as a 60 minute intravenous infusion, followed by a maintenance dose of 420 mg administered over a period of 30 to 60 minutes every 3 weeks thereafter.[1]  Both loading and maintenance dose is irrespective of patient body weight.[1]

                Combination treatment with Herceptin

                Perjeta is indicated in combination with Herceptin.[1] Perjeta and Herceptin should be administered sequentially and can be given in any order. When administered with Perjeta, follow a 3-weekly schedule for Herceptin administered either as [1]

                • Herceptin IV - an initial dose of 8 mg/kg followed every 3 weeks thereafter by 6 mg/kg, by intravenous infusion
                  • Herceptin SC - 600mg irrespective of the patient’s body weight every 3 weeks, by subcutaneous injection

                    Discontinue Perjeta if Herceptin treatment is discontinued.[1]

                    Dosing following delayed or missed treatment

                    If a patient experiences a delayed or missed dose of Perjeta, the next dose should be administered as soon as possible.[1] Do not wait until the next planned dose.

                    In clinical studies, if either Perjeta or Herceptin had to be delayed by a day or more, both treatments were required to be delayed for the same timeframe.[2,3] 

                    Depending on the time between two sequential doses, the patient may need to be administered the loading dose again.[1] Refer to Table 1 for recommendations on when re-loading doses may be required for Perjeta and Herceptin.

                    Table 1. Recommendations regarding delayed or missed doses

                    Then administer a...If the time between two sequential doses is... of less than 6 weeks and 6 weeks or longer for Perjeta, Herceptin IV and Herceptin SC

                    Once the patient has received either a loading or maintenance dose following the delay, the 3 weekly interval should be based on the latest dose, rather than the prior schedule.[1]

                    Dose delay example

                    A patient receives a maintenance dose of 420 mg Perjeta on 1st January. Their next dose is due on 22nd January, but because of travel plans, they are unable to receive it until 29th January (a 4 week interval). They should not receive their Herceptin IV dose on 22nd of January.

                    On 29th January, they should receive the maintenance doses of Perjeta 420 mg over 30 to 60 minutes and Herceptin 6 mg/kg IV.

                    Originally, they should have been due their following doses on 12th February, or 3 weeks from 22nd January. However, based on their new schedule, they will now be due to receive their next maintenance doses on 19th February, or 3 weeks from 29th January, and then every 3 weeks thereafter.

                    Switching from Phesgo

                    The Phase 2 PHranceSCa study evaluated patient preference for Phesgo, a fixed-dose subcutaneous injection combination of pertuzumab, trastuzumab and hyaluronidase, compared with IV Perjeta and IV Herceptin in the treatment of early HER2 positive breast cancer in the adjuvant setting.[4] In one arm of the study patients were administered 3 cycles of Phesgo every 3 weeks and then switched to receive 3 cycles of IV Perjeta and Herceptin every 3 weeks.

                    The initial dose of IV Perjeta after the switch from Phesgo was given at the maintenance dose of 420 mg if it was less than 6 weeks since their last treatment. If it had been 6 weeks or more since their last treatment, a loading dose of 840 mg was administered.[4]

                    Perjeta has been associated with infusion-related reactions, including events with fatal outcomes.[1] It is recommended to closely observe the patient during and for a set period following Perjeta infusions:

                    • First infusion — 60 minutes
                      • Subsequent infusions — 30 minutes

                        Complete the observation period prior to any subsequent dose of Herceptin or chemotherapy.[1]


                        1. Roche Internal Regulatory Report. Accessed 21 June 2023.
                          1. Protocol CLEOPATRA Trial: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. December 8, 2011. Available at Accessed on February 27, 2017.
                            1. Protocol for APHINITY Trial: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. July 21, 2017. Available at Accessed on June 5, 2017.
                              1. O'Shaughnessy J, Sousa S, Cruz J, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer 2021;152:223-232.

                                Welcome to Medically

                                The Roche Science Hub

                                This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                                Not a healthcare professional? Browse:

                                This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                                You are Leaving Medically

                                By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.